person · Reporting owner
Menzaghi Frederique Ph.D.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tvardi Therapeutics, Inc.
Report date February 01, 2024 · Filed February 05, 2024
Section 16 reporting ended · disclosed 2024-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 167,247 |
Reported balance
After 2024-02-01 transaction · row 1
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 13,500 · Balance 167,247 F1: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2018 Filed Nov 6, 2018 01:21 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 10,000 | $2.25 | $22,500.00 |
DisclosureSEC source: 0001209191-18-057306 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:00 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,000 | $19.00 | $57,000.00 |
DisclosureSEC source: 0001209191-18-041722 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,000 | $15.49 | $46,470.00 |
DisclosureSEC source: 0001209191-18-035933 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.4501 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 9,000 | $15.19 | $136,710.00 |
DisclosureSEC source: 0001209191-18-033520 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:35 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 57,750 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001209191-18-019400 · doc4.xml · derivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 57,750 shares Expires 2028-03-09 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:43 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,000 | $15.02 | $45,060.00 |
DisclosureSEC source: 0001209191-18-011372 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 22:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 15,000 | $15.00 | $225,000.00 |
DisclosureSEC source: 0001209191-18-005679 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:36 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-17-059985 · doc4.xml · derivative · entry 2 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2017-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:36 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 20,000 | $2.48 | $49,600.00 |
DisclosureSEC source: 0001209191-17-059985 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2017 Filed Aug 10, 2017 21:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001209191-17-048459 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 22:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001209191-17-045566 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 22:20 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0001209191-17-019914 · doc4.xml · derivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.